Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03516071 | A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC | PHASE2 | COMPLETED | 90 | — | — | May 17, 2017 | Jul 19, 2019 | Sep 4, 2019 | 15 | China |
Defined as the percentage of patients with complete response, partial response, or stable disease at 12 weeks from randomization by RECIST v1.1.
Defined as the time from random assignment to radiologic disease progression.
| Arm | Type | Description |
|---|---|---|
| Brivanib 800 mg, QD + BSC | EXPERIMENTAL | - |
| Brivanib 400 mg, BID + BSC | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Brivanib 800 mg, QD | DRUG | Brivanib Alaninate 800 mg QD, PO |
| Brivanib 400 mg, BID | DRUG | Brivanib Alaninate 400 mg BID, PO |
Inclusion Criteria: * 18-75 years, male or female * Histologically or cytologically confirmed or the clinical diagnosis standard confirmed hepatocellular carcinoma (HCC) patients * Failure or intolerance to prior treatment with chemotherapy and/or targeted therapy * Liver function status Child-Pugh...